Cellectar Biosciences (CLRB) Share-based Compensation (2010 - 2026)
Cellectar Biosciences (CLRB) posted Share-based Compensation of $567788.0 for Q4 2025, little changed sequentially from $567788.0 in Q3 2025, and down 61.77% YoY from $1.5 million in Q4 2024.
Cellectar Biosciences (CLRB) Share-based Compensation (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Share-based Compensation for 16 years, with the latest figure at $567788.0 in Q4 2025.
- Quarterly Share-based Compensation fell 61.77% year-over-year to $567788.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (down 42.88% YoY) and the FY2025 annual result came in at $5.5 million, up 28.02% from the prior year.
- Share-based Compensation steadied at $567788.0 in Q4 2025 per CLRB's latest filing, from $567788.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.5 million in Q4 2024 and troughed at $37211.0 in Q3 2022.
- A 5-year average of $517808.2 and a median of $414231.5 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation slumped 89.62% in 2022, then soared 998.35% in 2023.
- Over 5 years, Share-based Compensation stood at $377848.0 in 2021, then fell by 4.34% to $361447.0 in 2022, then jumped by 200.03% to $1.1 million in 2023, then jumped by 36.95% to $1.5 million in 2024, then plunged by 61.77% to $567788.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $567788.0, $567788.0, and $666990.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | - |
| 10 | Cellectar Biosciences | 6.52 Mn | 6.52 Mn | - | 428,306.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 428,306.00 |
| Jun 30, 2026 | 428,306.00 |
| Dec 31, 2025 | 567,788.00 |
| Dec 31, 2025 | 567,788.00 |
| Sep 30, 2025 | 567,788.00 |
| Sep 30, 2025 | 567,788.00 |
| Jun 30, 2025 | 666,990.00 |
| Jun 30, 2025 | 666,990.00 |
| Mar 31, 2025 | 461,138.00 |
| Mar 31, 2025 | 461,138.00 |
| Dec 31, 2024 | 1.49 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 799,249.00 |
| Jun 30, 2024 | 799,249.00 |
| Mar 31, 2024 | 454,363.00 |
| Mar 31, 2024 | 454,363.00 |
| Dec 31, 2023 | 1.08 Mn |
| Dec 31, 2023 | 1.08 Mn |